Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 4.07M P/E - EPS this Y 97.40% Ern Qtrly Grth -
Income -13.04M Forward P/E -0.30 EPS next Y -300.00% 50D Avg Chg -37.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -83.00%
Dividend N/A Price/Book 0.11 EPS next 5Y - 52W High Chg -95.00%
Recommedations 1.50 Quick Ratio 2.76 Shares Outstanding 26.26M 52W Low Chg -
Insider Own 0.86% ROA -33.54% Shares Float 19.58M Beta -0.26
Inst Own 26.37% ROE -142.88% Shares Shorted/Prior 73.44K/86.35K Price 0.56
Gross Margin - Profit Margin - Avg. Volume 270,170 Target Price 3.67
Oper. Margin - Earnings Date May 7 Volume 93,777 Change -5.08%
About Kiora Pharmaceuticals, Inc.

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

Kiora Pharmaceuticals, Inc. News
04/11/24 Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study
04/05/24 Kiora Pharmaceuticals to Present at Upcoming Investor Conferences
03/28/24 Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting
03/25/24 Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases
03/08/24 Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye
01/31/24 Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
01/31/24 Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clinical Development, Regulatory and Commercial Milestones, Plus Commercial Royalties
11/17/23 Breaking ground in vision restoration: Kiora Pharmaceuticals reveals promising results with KIO-301
11/09/23 Kiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis Pigmentosa
11/04/23 AAO Late-Breaking: Kiora's Small Molecule Photoswitch Demonstrates Meaningful Vision Improvements in Blind Patients with Retinitis Pigmentosa
10/16/23 Kiora Pharmaceuticals to Participate in the Lytham Partners Fall 2023 Investor Conference
10/03/23 Kiora Pharmaceuticals Receives Investigational New Drug Application Approval to Expand Phase 1b Study of KIO-301 in Inherited Retinal Diseases; To Enroll Patients with Choroideremia and Additional Patients with Late-Stage Retinitis Pigmentosa
09/21/23 Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years
09/18/23 Kiora Pharmaceuticals Completes Last Patient, Last Visit in Phase 1B Trial of KIO-301 in Patients with Retinitis Pigmentosa
09/14/23 Kiora Pharmaceuticals to Present Topline Results from the ABACUS Study at American Academy Ophthalmology (AAO); Phase 1b Study Evaluating KIO-301 in Retinitis Pigmentosa
09/01/23 Kiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27
08/29/23 Kiora Pharmaceuticals and the Choroideremia Research Foundation to Host Webinar on the Development of Molecular Photoswitches for Inherited Retinal Diseases
08/23/23 Is Kiora Pharmaceuticals Significantly Undervalued? A Comprehensive Valuation Analysis
08/23/23 Kiora Pharmaceuticals Granted U.S. and European Patents for Local Ocular Delivery of the KIO-100 Family of Compounds; New IP Specifically Includes Treatment of Posterior Non-Infectious Uveitis
08/22/23 Kiora Pharmaceuticals Taps B2i Digital to Deploy Data-Driven Investor Awareness Program
KPRX Chatroom

User Image TheButchers Posted - 11 hours ago

@bearishbull69 $KPRX that and more than 50M warrants diluting any upside but also the many licensing and business obligations on projects they don’t have researchers assigned to and are pretty much mort.

User Image bearishbull69 Posted - 14 hours ago

$KPRX Behaving as expected with a r/s on the table. Waiting to see how management responds after it's said and done before adding more. Just a waiting game for me now.

User Image TheButchers Posted - 2 days ago

$KPRX Typically the lead “investors” like Lind and Lincoln Park who have participated in Kiora/Eyegate financings will liquidate their common shares within six months of purchase and will use the warrants for hedging. It is a fatal point in the trading of the securities because the price has already fallen below the 55 cent purchase price and they are each bagholding 2 warrants for every share they own and got for 55 cents. They proper Avenue is to short the stock using warrants as collateral. It is going to be a poop show as the shareholders approve the RS. This will fall to 20 cents a share by the end of the year if not worse. It happens all the time with this management and Board of Directors. The 1:10 RS would put the culminating RS factor since the IPO to 1:6000!

User Image TheButchers Posted - 2 days ago

@FireDepartment $KPRX we really don’t know if the technology works or not and it’s years a ways until any FDA NDA filing.

User Image FireDepartment Posted - 2 days ago

$KPRX so they’re just not going to announce the patent news?

User Image TheButchers Posted - 2 days ago

@Emxc2 $KPRX This will need to reverse split at 1:10 by June and warrant holders of more than 50M warrants are trying to unload their own shares to recoup their prior investment and it is already below water from their 55 purchase price for one share and 2 warrants.

User Image Emxc2 Posted - 2 days ago

$KPRX any suggestions on this ? good entry pt ?

User Image JonTripathi Posted - 2 days ago

$KPRX mm signal on level 2?

User Image TheButchers Posted - 2 days ago

$KPRX People: Kiora is a long ways away from any potential product approval. This is their MO. Tell the world they can get you the world but take forever in getting to even first base. They don’t even know the clinical pathway to approval yet. By the time investors figure out that they are at a dead end they find some other technology or story to tell you.

User Image CanadianSalmonGal Posted - 2 days ago

$KPRX This grant is ultimately about providing greater clarity on the pathway to approvability."

User Image Philheath88 Posted - 2 days ago

$KPRX If the deal going through at $5 why we only at $2

User Image FireDepartment Posted - 3 days ago

$KPRX whyd they slap our peepee?

User Image diamondhandzape Posted - 3 days ago

$KPRX bought more lfg to $3+ 🚀🚀🚀🚀

User Image TheButchers Posted - 3 days ago

$KPRX It’s pump and dump because the MO of the warrants holders who participated in the last deal want to short above the 55 cent sales price. Overall there are more than 50M warrants outstanding of which a significant portion have an exercise price of 55 cents. AH isn’t buying it and with about 435K shares traded after hours it is struggling to maintain a line at 50 cents back to where it was just before the pump and dump initiation.

User Image diamondhandzape Posted - 3 days ago

$KPRX $3 - $5? 🚀🚀🚀🚀

User Image FireDepartment Posted - 3 days ago

$KPRX last chance to get in I guess

User Image RETAlerts Posted - 3 days ago

$KPRX at 0.630 is starting to show some signs of a stronger breakout, we can see a couple of zones ahead that need to be broken, now up 10% since our first mention. (15 minute delay)

User Image RETAlerts Posted - 3 days ago

$KPRX at 0.611 is moving a little and is 5% up from landing on our scanner, it will take a larger gap to draw some attention, follow us for updates. (15 minute delay)

User Image Bigeyes2 Posted - 3 days ago

$KPRX Swing-Long

User Image timelesstrades Posted - 3 days ago

$KPRX added

User Image StockAuthority Posted - 3 days ago

$KPRX added some on this AH rip then dip

User Image harristradez Posted - 3 days ago

$KPRX watching the .64 break out going into the AH. The FF is a little big so be careful

User Image diamondhandzape Posted - 3 days ago

$KPRX 🚨🚨🚨🚨🚨 Lfg to $10+ 🚀🚀🚀🚀🚀🚀🚀🚀🚀

User Image troyville75 Posted - 3 days ago

$KPRX Big green candle. Run for days please!!

User Image AlertsAndNews Posted - 3 days ago

$KPRX patent news into the close here

User Image US_Patent_Plays Posted - 3 days ago

$KPRX Granted US Patent For "POLYMORPHS OF A DIHYDROOROTATE DEHYDROGENASE DHOD INHIBITOR (FOR DISEASES SUCH AS ARTHRITIS, ALZHEIMER'S, CANCER)". Status Allowed = Patent Granted. Conventional Publication Imminent. https://patentcenter.uspto.gov/applications/18172656?application=

User Image TheButchers Posted - 3 days ago

$KPRX

User Image JonTripathi Posted - 4 days ago

$KPRX zero liquidity

User Image KioraIR Posted - 4 days ago

$KPRX Our EVP of Finance, Melissa Tosca, discussed our pipeline, partnerships, and milestones at last week's Noble Emerging Growth Conference. If you missed the live presentation, you can now view the replay from our IR homepage - https://ir.kiorapharma.com/

User Image TheButchers Posted - 1 week ago

@1logicaltrader $KPRX Often investors feel ok when they trade in the moment..It is when the stock drops when they start getting upset.

Analyst Ratings
HC Wainwright & Co. Buy Mar 27, 24
HC Wainwright & Co. Buy Feb 9, 24
HC Wainwright & Co. Buy Nov 13, 23
HC Wainwright & Co. Buy Nov 6, 23
HC Wainwright & Co. Buy Aug 24, 23
HC Wainwright & Co. Buy Aug 14, 23
Maxim Group Buy Aug 9, 23
HC Wainwright & Co. Buy May 12, 23
HC Wainwright & Co. Buy Mar 24, 23